Anja Kammesheidt, Ph.D.
Chief Scientific Officer
Anja Kammesheidt, Ph.D., received her bachelor and doctoral degrees in biological sciences from the University of California, Irvine, with a focus on molecular neurobiology. Her early research interests centered on Alzheimer’s disease models and viral vector gene transfer systems. After completing her postdoctoral training at the University of California, San Diego, where she studied protein-targeting mechanisms at the neuromuscular junction, she joined Purdue Pharma as a research scientist working on neuropathic pain targets.
Dr. Kammesheidt joined the molecular diagnostics space in 2002, serving as chief scientific officer at Ambry Genetics for a 10-year period. She then focused on oncology, working on genomics-based personalized diagnostics at Agendia (Irvine USA and Amsterdam NL), where she was also directing translational science projects. Dr. Kammesheidt joined Pathway Genomics in February 2015 as the vice president of research and development where she oversees all assay development activities.